You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Zanubrutinib

Showing 26 - 50 of 104
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Leukemia, Lymphocytic, Chronic, B-Cell Trial in New York (Zanubrutinib Pill, Venetoclax Pill, Obinutuzumab Injection)

Not yet recruiting
  • Leukemia, Lymphocytic, Chronic, B-Cell
  • Zanubrutinib Pill
  • +2 more
  • New York, New York
    Weill Cornell Medicine/NewYork-Presberteryian Hospital
Dec 6, 2022

CNS Lymphoma Trial in Beijing (Zanubrutinib)

Recruiting
  • CNS Lymphoma
  • Zanubrutinib
  • Beijing, Beijing, China
    Peking University People's Hospital
Aug 1, 2022

Relapsed/Refractory Marginal Zone Lymphoma Trial in Westbury (Zanubrutinib, Rituximab, Lenalidomide)

Recruiting
  • Relapsed/Refractory Follicular Lymphoma
  • Marginal Zone Lymphoma
  • Zanubrutinib
  • +3 more
  • Westbury, New York
    Clinical Research Alliance, Inc.
Nov 14, 2022

Relapsed or Refractory B-cell Non-Hodgkin Lymphoma Trial in Suzhou (Obinutuzumab, Zanubrutinib, Lenalidomide)

Enrolling by invitation
  • Relapsed or Refractory B-cell Non-Hodgkin Lymphoma
  • Suzhou, Jiangsu, China
    the First Affiliated Hospital of Soochow University
Mar 22, 2023

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma Trial in Duarte (procedure, biological, drug)

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • Small Lymphocytic Lymphoma
  • Biospecimen Collection
  • +4 more
  • Duarte, California
    City of Hope Medical Center
Jan 30, 2023

Mantle Cell Lymphoma, Newly-diagnosed Mantle Cell Lymphoma Trial in Guangzhou (Zanubrutinib and Rituximab, R-DHAOx, Zanubrutinib

Recruiting
  • Mantle Cell Lymphoma
  • Newly-diagnosed Mantle Cell Lymphoma
  • Zanubrutinib and Rituximab
  • +2 more
  • Guangzhou, Guangdong, China
  • +2 more
May 6, 2022

HLH Trial in Beijing (Zanubrutinib)

Recruiting
  • HLH
  • Zanubrutinib
  • Beijing, China
    Beijing Friendship Hospital, Capital Medical University
Apr 2, 2022

Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Newly Diagnosed Trial in Tianjin (Zanubrutinib, Fludarabine,

Not yet recruiting
  • Chronic Lymphocytic Leukemia
  • +2 more
  • Zanubrutinib, Fludarabine, cyclophosphamide and rituximab
  • Zanubrutinib, bendamustine, rituximab
  • Tianjin, Tianjin, China
    Institute of Hematology & Blood Diseases Hospital
Mar 18, 2022

Secondary CNS Lymphoma Trial in Beijing (Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab)

Recruiting
  • Secondary Central Nervous System Lymphoma
  • Zanubrutinib, high-dose methotrexate (HD-MTX), rituximab
  • Beijing, Beijing, China
    Peking University Cancer Hospital & Institute
May 25, 2022

Neuromyelitis Optica Trial in Beijing (zanubrutinib)

Recruiting
  • Neuromyelitis Optica
  • zanubrutinib
  • Beijing, Beijing, China
    XuanWu Hospital
May 15, 2022

Zanubrutinib in Waldenström's Macroglobulinemia (ARIADNE)

Recruiting
  • Waldenström's Macroglobulinemia
  • Zanubrutinib
  • Salzburg, Austria
  • +1 more
May 2, 2022

Lupus Nephritis Trial in Guangdong (Zanubrutinib, Placebo)

Recruiting
  • Lupus Nephritis
  • Zanubrutinib
  • Placebo
  • Guangdong, Guangzhou, China
    Guangdong General Hospital
Apr 19, 2022

Overall Survival Trial in Qingdao (Rituximab + zanubrutinib + lenalidomide)

Recruiting
  • Overall Survival
  • Rituximab + zanubrutinib + lenalidomide
  • Qingdao, Shandong, China
    Qingdao central Hospital
May 22, 2022

B-cell Malignancies Trial in Australia (Zanubrutinib, Fluconazole, Diltiazem)

Completed
  • B-cell Malignancies
  • Zanubrutinib
  • +4 more
  • Concord, New South Wales, Australia
  • +6 more
Jul 18, 2022

Immune Thrombocytopenia, Bruton Tyrosine Kinase Trial in Beijing (Zanubrutinib)

Recruiting
  • Immune Thrombocytopenia
  • Bruton Tyrosine Kinase
  • Zanubrutinib
  • Beijing, Beijing, China
    Peking University Insititute of Hematology, Peking University Pe
Mar 6, 2022

Immune Thrombocytopenia Trial (Zanubrutinib, Dexamethasone)

Not yet recruiting
  • Immune Thrombocytopenia
  • (no location specified)
May 6, 2022

Recurrent Refractory Mantle Cell Lymphoma

Recruiting
  • Mantle Cell Lymphoma
    • Beijing, Beijing, China
      Peking University Third Hospital
    Aug 1, 2022

    Immune Thrombocytopenia Trial in Beijing (Zanubrutinib, Eltrombopag)

    Not yet recruiting
    • Immune Thrombocytopenia
    • Beijing, Beijing, China
      Peking University Insititute of Hematology, Peking University Pe
    May 6, 2022

    Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Lymphoma Trial in Boston (Venetoclax, Zanubrutinib)

    Recruiting
    • Chronic Lymphocytic Leukemia (CLL)
    • Small Lymphocytic Lymphoma
    • Boston, Massachusetts
    • +2 more
    Mar 16, 2022

    Immune Thrombocytopenia, Treatment Trial in Tianjin (Zanubrutinib)

    Recruiting
    • Immune Thrombocytopenia
    • Treatment
    • Zanubrutinib
    • Tianjin, Tianjin, China
      Chinese Academy of Medical Science and Blood Disease Hospital
    Jan 19, 2022

    Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia, Transformed Chronic

    Not yet recruiting
    • Recurrent Transformed Chronic Lymphocytic Leukemia
    • +7 more
    • Biospecimen Collection
    • +9 more
    • Columbus, Ohio
      Ohio State University Comprehensive Cancer Center
    May 15, 2023

    Chronic Lymphocytic Leukemia (CLL), Small Lymphocytic Leukemia (SLL) Trial in United States (Zanubrutinib, Obinutuzumab,

    Recruiting
    • Chronic Lymphocytic Leukemia (CLL)
    • Small Lymphocytic Leukemia (SLL)
    • Zanubrutinib
    • +2 more
    • Evanston, Illinois
    • +7 more
    Sep 9, 2022

    Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Follicular Lymphoma Trial in Australia, China (BGB-10188,

    Recruiting
    • Chronic Lymphocytic Leukemia
    • +9 more
    • Adelaide, Australia
    • +12 more
    Jan 6, 2023

    Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Trial in Houston (Rituximab, Zanubrutinib)

    Recruiting
    • Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
    • Rituximab
    • Zanubrutinib
    • Houston, Texas
      M D Anderson Cancer Center
    Jul 9, 2022

    Diffuse Large B-cell Lymphoma(DLBCL) Trial in Shanghai (Zanubrutinib + R-CHOP)

    Recruiting
    • Diffuse Large B-cell Lymphoma(DLBCL)
    • Zanubrutinib + R-CHOP
    • Shanghai, China
      Fudan University Shanghai Cancer Center
    Feb 10, 2022